CYTO实时信号 | 通过Getagraph.com最大化利润

出售 121377 min ago

@ $1.986

发出时间: 10 Feb 2024 @ 04:25

回报率: -17.42%

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Stats
今日成交量	30 000.00
平均成交量	1.21M
市值	3.67M
EPS	$0 ( 2024-04-10 )
下一个收益日期	( $0 ) 2024-05-16
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.100
ATR14	$0.0200 (1.22%)

Insider Trading

Date	Person	Action	Amount	type
2008-05-08	Carter Stephen	Sell	10 000	Common Stock
2008-05-08	Lokay Kevin G	Sell	185 439	Common Stock
2008-05-08	Lokay Kevin G	Sell	100 000	Options to Purchase Common Stock
2008-05-08	Mollica Joseph A	Sell	10 000	Common Stock
2007-11-13	Lokay Kevin G	Buy	500 000	Options to purchase Common Stock par value $0.01

INSIDER POWER
0.00
Last 33 transactions
Buy: 1 218 228 \| Sell: 315 439

音量相关性

長: 0.00 (neutral)

短: -0.33 (neutral)

Signal:(49.257) Neutral

Altamira Therapeutics 相关性

10 最正相关
PIII	0.951
PROC	0.95
DISH	0.948
LGMK	0.945
AHCO	0.944
LGHL	0.942
EVLO	0.942
TTEC	0.941
MDRX	0.941
UPC	0.94

10 最负相关
VKTX	-0.965
JMAC	-0.965
IQ	-0.96
DKDCA	-0.96
CMPO	-0.957
HHGC	-0.956
IVCP	-0.956
AIB	-0.951
OVLY	-0.951
ACLS	-0.951

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Altamira Therapeutics 相关性 - 货币/商品

0.27
( neutral )

-0.12
( neutral )

0.00
( neutral )

0.32
( neutral )

0.39
( neutral )

0.37
( neutral )

Altamira Therapeutics 财务报表

Annual	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-14.80

FY	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-14.80

FY	2022
营收:	$305 616
毛利润:	$-1.14M (-372.44 %)
EPS:	$-29.13

FY	2021
营收:	$63 882.00
毛利润:	$-2.18M (-3 407.33 %)
EPS:	$-3.24

Financial Reports:

No articles found.

Altamira Therapeutics

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.